Assessing Merck and Moderna’s mRNA cancer vaccine

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. What is Adam doing in Spain? How did doctors react to detailed data on Merck and Moderna’s mRNA cancer vaccine? And what are the next big advances in oncology? On this week’s episode of “The Readout LOUD,” STAT’s biotech podcast, we bring on our colleague Andrew Joseph to discuss the latest cancer data presented at the annual meeting of the European Society for Medical Oncology. We also make an announcement about the podcast. For more on Merck and Moderna’s data, go here; for more on Amgen’s lung cancer data, go here; for more on Roche’s results, go here; and for more of STAT’s coverage of the ESMO conference, go here. Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.